Pancreas最新文献_第2页

Outcomes of Post-Endoscopic Ultrasound Pancreatic Cancer Compared to Detected Pancreatic Cancer: A Multicenter Cohort Study. 内镜下超声诊断胰腺癌与检测胰腺癌的结果比较：一项多中心队列研究。

IF 2.2 4区医学

Pancreas Pub Date : 2026-11-01 Epub Date: 2026-07-07 DOI: 10.1097/MPA.0000000000002699

Rahul Karna, Himsikhar Khataniar, Omar Al Ta'ani, Suchapa Arayakarnkul, Mohammad Bilal, Shifa Umar

{"title":"Outcomes of Post-Endoscopic Ultrasound Pancreatic Cancer Compared to Detected Pancreatic Cancer: A Multicenter Cohort Study.","authors":"Rahul Karna, Himsikhar Khataniar, Omar Al Ta'ani, Suchapa Arayakarnkul, Mohammad Bilal, Shifa Umar","doi":"10.1097/MPA.0000000000002699","DOIUrl":"10.1097/MPA.0000000000002699","url":null,"abstract":"Background and aims: Endoscopic ultrasound (EUS) can detect premalignant lesions in pancreas. Despite advances in training, EUS remains an operator-dependent procedure, and interval pancreatic cancer (PC) can be diagnosed after a preceding cancer-negative EUS. We aim to study outcomes of PC occurring after a EUS negative for cancer.Methods: We utilized the TriNetX multi-institutional database to assess patients with PC and a preceding EUS. Patients whose EUS occurred less than 6 months before PC diagnosis were categorized as detected pancreatic cancer (D-PC), while those with EUS that did not detect PC between 6 and 18 months before PC diagnosis were categorized as post-EUS-pancreatic cancer (PEPC). Propensity-matched cohort analysis was performed after controlling for covariates to assess surgery, chemotherapy, hospitalization, and all-cause mortality.Results: Out of 20,828 included PC patients, 5.4% (n=1127) were PEPC and 94.6% (n=19,701) were D-PC. At 3 years, PEPC cohort had significantly lower chemotherapy utilization (33.07% vs. 45.46%), surgery (9.53% vs. 22.37%), all-cause hospitalization (53.57% vs. 69.70%), and all-cause mortality (27.90% vs. 33.42%) compared with D-PC. Predictors of mortality in PEPC cohort include White race (aHR 1.191), type 2 diabetes mellitus (aHR 1.144), nicotine use (aHR 1.233), and location in head (aHR 1.319) and body (aHR 1.225) of pancreas.Conclusions: Nearly 5.4% pancreatic cancer occur after negative EUS in the previous 6-18 months. D-PC had higher chance of surgical resection and chemotherapy but also higher rates of mortality at 3 years. Further large-scale studies with patient and procedure-level data assessment to allow root-cause analysis are needed to determine its etiology and associated factors to limit its incidence.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":"e1014-e1019"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

APA 2026 Abstracts. APA 2026摘要

IF 2.2 4区医学

Pancreas Pub Date : 2026-11-01 Epub Date: 2026-10-13 DOI: 10.1097/MPA.0000000000002724

引用次数: 0

Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. 日本胰腺肿瘤的临床统计和结果：一项使用日本胰腺癌登记处的回顾性队列研究。

IF 2.2 4区医学

Pancreas Pub Date : 2026-11-01 Epub Date: 2026-06-25 DOI: 10.1097/MPA.0000000000002694

Masamichi Mizuma, Shinya Hirakawa, Hisateru Tachimori, Hiraku Kumamaru, Takao Itoi, Shinichi Egawa, Manabu Kawai, Yuzo Kodama, Sohei Satoi, Kohei Nakata, Shin Hamada, Ichiro Yasuda, Yoshihiro Kakeji, Ken Shirabe, Michiaki Unno, Tooru Shimosegawa, Kazuichi Okazaki, Yoshifumi Takeyama, Atsushi Masamune

{"title":"Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry.","authors":"Masamichi Mizuma, Shinya Hirakawa, Hisateru Tachimori, Hiraku Kumamaru, Takao Itoi, Shinichi Egawa, Manabu Kawai, Yuzo Kodama, Sohei Satoi, Kohei Nakata, Shin Hamada, Ichiro Yasuda, Yoshihiro Kakeji, Ken Shirabe, Michiaki Unno, Tooru Shimosegawa, Kazuichi Okazaki, Yoshifumi Takeyama, Atsushi Masamune","doi":"10.1097/MPA.0000000000002694","DOIUrl":"10.1097/MPA.0000000000002694","url":null,"abstract":"Objectives: The Japan Pancreatic Cancer Registry (JPCR), managed by the Japan Pancreas Society, has adopted the National Clinical Database (NCD) platform for data registration. This study aimed to describe the nationwide annual trends and clinical outcomes of pancreatic neoplasms using this NCD-based registry (NCD-JPCR) for the first time.Methods: We analyzed data from the NCD-JPCR for pancreatic neoplasms registered between 2012 and 2018. The annual epidemiological trends and survival outcomes were evaluated for major pancreatic neoplasms, including invasive ductal carcinoma (IDC).Results: In total, 47,005 patients were registered from 1062 departments, with ∼600 departments contributing annually. IDC was the most common diagnosis (n=36,204; 77.0%), followed by intraductal (n=4498; 9.6%), cystic (n=2687; 5.7%), and pancreatic neuroendocrine neoplasms (n=2494; 5.3%). In the survival analysis of IDC, patients who underwent resection showed a significantly longer median overall survival (mOS) in 2015-2018 than in 2012-2014 [34.5 mo (n=17,328) vs. 29.7 mo (n=9623); P <0.0001]. Similarly, mOS for patients who did not undergo resection significantly improved in 2015-2018 compared with 2012-2014 [10.2 mo (n=5733) vs. 9.0 mo (n=3,326); P <0.0001].Conclusions: Treatment outcomes for IDC showed significant improvements from the early to the late 2010s for both patients who did and did not undergo resection. These findings may reflect nationwide progress in the multidisciplinary management of pancreatic cancer in Japan.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":"e995-e1005"},"PeriodicalIF":2.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148332058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineering Human SPINK1 for Improved Therapeutic Trypsin Inhibition. 工程人类SPINK1改善治疗性胰蛋白酶抑制。

IF 2.2 4区医学

Pancreas Pub Date : 2026-10-14 DOI: 10.1097/MPA.0000000000002729

Zoltán Attila Nagy, Gergő Berke, Anasztázia Erzsébet Kun, Gyula Hoffka, András Szabó, Miklós Sahin-Tóth

引用次数: 0

Effects of Febuxostat, a Non-purine Xanthine Oxidase Inhibitor, on Cerulein-induced and L-Arginine-induced Acute Pancreatitis in Rats. 非嘌呤黄嘌呤氧化酶抑制剂非布司他对蓝蛋白和精氨酸诱导的大鼠急性胰腺炎的影响。

IF 2.2 4区医学

Pancreas Pub Date : 2026-10-14 DOI: 10.1097/MPA.0000000000002727

Tomoyuki Hamamoto, Ryo Yamaguchi, Sakurako Maita, Shigeo Akiyama, Yasumi Anan, Noriyoshi Fukushima

{"title":"Effects of Febuxostat, a Non-purine Xanthine Oxidase Inhibitor, on Cerulein-induced and L-Arginine-induced Acute Pancreatitis in Rats.","authors":"Tomoyuki Hamamoto, Ryo Yamaguchi, Sakurako Maita, Shigeo Akiyama, Yasumi Anan, Noriyoshi Fukushima","doi":"10.1097/MPA.0000000000002727","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002727","url":null,"abstract":"Objectives: The effects of xanthine oxidase (XO) inhibitors on acute pancreatitis (AP) have only been reported for allopurinol, with controversial results. We investigated the effects of febuxostat, a potent and selective XO inhibitor, in two AP rat models and compared the results with those of allopurinol.Methods: Using cerulein- and L-arginine-induced AP models, we evaluated the effects of the two XO inhibitors based on histopathological and biochemical parameters, including serum amylase, lipase, blood urea nitrogen, pancreatic malondialdehyde, glutathione peroxidase, reduced-to-total glutathione ratio, and serum/pancreatic XO levels.Results: In cerulein-induced AP, concurrent administration significantly reduced serum and pancreatic XO activities in the Allopurinol (200 mg/kg) and Febuxostat (15 and 30 mg/kg) groups to 2.8%/35.8%, 0.6%/4.9%, and 0.3%/0.7% of controls, respectively (P <0.05). Therapeutic administration showed similar decreases to 4.9%/56.1% and 0.8%/1.8% of controls (P <0.05) for Allopurinol (200 mg/kg) and Febuxostat (30 mg/kg), respectively. In L-arginine-induced AP, concurrent allopurinol and febuxostat administration reduces XO activities to 50.8% (P <0.05)/102.8% and 7.8% (P <0.01)/78% of controls, respectively. Therapeutic administration produced comparable decreases to 2.7% (P <0.05)/87.2% and 2.2% (P <0.05)/70% of controls for Allopurinol (200 mg/kg×2) and Febuxostat (15 mg/kg×2), respectively. These reductions were greater with febuxostat than with allopurinol. Nevertheless, febuxostat and allopurinol failed to alleviate AP.Conclusions: Our results suggest that XO inhibition alone does not have a therapeutic effect　on AP and XO is not significantly involved in the progression of AP in either AP model.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149183349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Care Gaps in Pancreatic Enzyme Replacement Therapy: A Survey of Real-World Practice Patterns in the United States. 胰酶替代疗法的护理差距：美国现实世界实践模式的调查。

IF 2.2 4区医学

Pancreas Pub Date : 2026-10-02 DOI: 10.1097/MPA.0000000000002721

Bradford Chong, Jennifer Whitlock, Kalpesh Patel, Douglas Dylla, Alicia J Noonan, Eric Shen, Viviana Garcia-Horton, Min Yang, Marie Louise Edwards, Jodie A Barkin

{"title":"Care Gaps in Pancreatic Enzyme Replacement Therapy: A Survey of Real-World Practice Patterns in the United States.","authors":"Bradford Chong, Jennifer Whitlock, Kalpesh Patel, Douglas Dylla, Alicia J Noonan, Eric Shen, Viviana Garcia-Horton, Min Yang, Marie Louise Edwards, Jodie A Barkin","doi":"10.1097/MPA.0000000000002721","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002721","url":null,"abstract":"Objectives: To describe real-world clinical practice patterns among U.S.-based healthcare providers (HCPs) regarding the use of pancreatic enzyme replacement therapy (PERT) in the management of exocrine pancreatic insufficiency (EPI).Methods: A cross-sectional, online, double-blinded survey was conducted among a panel of HCPs, including physicians, nurse practitioners, and physician assistants, with ≥3 years of experience treating EPI and recent PERT prescribing activity. The survey collected de-identified data on HCP demographics, aggregated patient characteristics, PERT prescribing patterns, and follow-up practices. Descriptive statistics were used to summarize the data.Results: Of the 354 HCPs screened, 250 completed the survey. Participants were mainly physicians (88%), predominantly in private practice (69%), with an average of 20 years of clinical experience. Initial PERT doses prescribed were <30,000 lipase units (LU) per meal (12%), 30,000-59,000 LU/meal (58%), and ≥60,000 LU/meal (14%). Only 60% of HCPs included snack dosing instructions, and follow-up for dose titration occurred most frequently at one month post-initiation (60%). PERT underdosing and omitted dosing instructions for snacks were common.Conclusion: Real-world PERT prescribing for EPI in the U.S. frequently falls short of guideline-recommended dosing and follow-up is often delayed. Providing patients with instructions snack dosing and early reassessment represent gaps in EPI care, underscoring the importance of HCP training and education to optimize outcomes of EPI treatment.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149113284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Detection of Pancreatic Adenocarcinoma Using Triple-phase contrast-enhanced Computed Tomography: A Case-control Study. 使用三期增强计算机断层扫描早期检测胰腺腺癌：一项病例对照研究。

IF 2.2 4区医学

Pancreas Pub Date : 2026-10-01 DOI: 10.1097/MPA.0000000000002712

Tsuyoshi Hayashi, Yoshihisa Kodama, Yasuo Sakurai, Hajime Yamazaki, Yukiko Takigawa, Haruka Toyonaga, Tatsuya Ishii, Toshifumi Kin, Kuniyuki Takahashi, Akio Katanuma

{"title":"Early Detection of Pancreatic Adenocarcinoma Using Triple-phase contrast-enhanced Computed Tomography: A Case-control Study.","authors":"Tsuyoshi Hayashi, Yoshihisa Kodama, Yasuo Sakurai, Hajime Yamazaki, Yukiko Takigawa, Haruka Toyonaga, Tatsuya Ishii, Toshifumi Kin, Kuniyuki Takahashi, Akio Katanuma","doi":"10.1097/MPA.0000000000002712","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002712","url":null,"abstract":"Objectives: To investigate the imaging findings of the triple-phase computed tomography (CT), which was performed prior to definitive diagnoses in patients with Pancreatic ductal adenocarcinoma (PDAC).Methods: The single-center, retrospective, case-control study included patients with PDAC who underwent triple-phase CT 3-36 months prior to definitive diagnosis (pre-diagnostic CT) between January 2007 and March 2018 in Teine Keijinkai hospital. Triple-phase CT in sex- and age-matched patients without PDAC appearance in a 4:1 ratio were selected as controls. Findings were detected from each of the five divided pancreatic sections on pre-diagnostic CT by radiologists' reviews, and were analyzed by comparison with CT at the definitive diagnosis (diagnostic CT) to investigate risk ratios.Results: Pre-diagnostic CTs were investigated in 190 and 760 sections with 38 PDAC and 152 control patients. In the diagnostic CT, 50 PDAC-positive and 900 negative sections were detected, respectively. In pre-diagnostic CT review, some findings were shown in 17 (34.0%) and 18 (2.0%) sections among PDAC-positive and negative sections, respectively, and the total number of findings was 46 and 28 in PDAC-positive and negative sections, respectively. Finally, different attenuation of pancreatic parenchyma in each phase, MPD stenosis, and focal pancreatic parenchymal atrophy were significantly correlated with the risk of PDAC.Conclusions: While some findings may already appear on the pre-diagnostic CT in one-third of the PDAC-positive sections, an accurate and detailed review in triple-phase CT is indispensable to detect early PDAC in clinical practice.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149113259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between Serum Human Satellite II RNA and miR-21-5p Levels and Time to Pancreatic Cancer Diagnosis in a Prospective Population-based Study. 在一项基于人群的前瞻性研究中，血清人卫星II RNA和miR-21-5p水平与胰腺癌诊断时间之间的关系

IF 2.2 4区医学

Pancreas Pub Date : 2026-09-22 DOI: 10.1097/MPA.0000000000002723

Takahiro Seimiya, Tatsunori Suzuki, Genso Notoya, Chikako Shibata, Yousuke Nakai, Keitaro Matsuo, Kenji Wakai, Rieko Okada, Nobuaki Michihata, Kiyonori Kuriki, Kosuke Kashiwabara, Takahiro Kishikawa, Motoyuki Otsuka, Mitsuhiro Fujishiro

{"title":"Association between Serum Human Satellite II RNA and miR-21-5p Levels and Time to Pancreatic Cancer Diagnosis in a Prospective Population-based Study.","authors":"Takahiro Seimiya, Tatsunori Suzuki, Genso Notoya, Chikako Shibata, Yousuke Nakai, Keitaro Matsuo, Kenji Wakai, Rieko Okada, Nobuaki Michihata, Kiyonori Kuriki, Kosuke Kashiwabara, Takahiro Kishikawa, Motoyuki Otsuka, Mitsuhiro Fujishiro","doi":"10.1097/MPA.0000000000002723","DOIUrl":"https://doi.org/10.1097/MPA.0000000000002723","url":null,"abstract":"Objectives: To investigate the temporal relationship between the pancreatic ductal adenocarcinoma (PDAC) index, combining serum human satellite II (HSATII) RNA and miR-21-5p measurements, and pancreatic cancer diagnosis in a prospective population-based study.Methods: We conducted a case-control study nested within the Japan Multi-institutional Collaborative Cohort (J-MICC) Study of over 92,000 participants. Serum samples were collected from 45 individuals who developed pancreatic cancer within 2 years of blood collection and 45 matched controls. We measured serum HSATII RNA and miR-21-5p levels using TRAP-ddPCR and calculated the PDAC index. Statistical analyses included Wilcoxon signed-rank tests, conditional logistic regression, and Cox proportional hazards models.Results: The PDAC index was significantly higher in pancreatic cancer cases compared to controls ( P =0.043), with the strongest difference observed in cases diagnosed within 0.3 years of blood collection ( P =0.046). A significant negative correlation between the PDAC index and time to diagnosis was observed in cases (R=-0.32, P =0.030). Cox proportional hazards analysis revealed a significant association between the PDAC index and time to pancreatic cancer diagnosis (HR=1.3, P =0.024). The AUC of PDAC index was 0.64 for cases diagnosed within 0.3 years.Conclusions: The PDAC index showed a possible association with proximity of pancreatic cancer diagnosis, with higher values observed closer to clinical diagnosis. While these preliminary findings should be interpreted in light of the study limitations, they provide a rationale for further evaluation of the PDAC index in larger studies with longer follow-up periods.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149113223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pancreatic Actinomycosis Caused by Actinomyces naeslundii Presenting as Acute Obstructive Suppurative Pancreatic Ductitis. 由奈氏放线菌引起的胰腺放线菌病表现为急性梗阻性化脓性胰腺导管炎。

IF 2.2 4区医学

Pancreas Pub Date : 2026-09-21 DOI: 10.1097/MPA.0000000000002715

Sho Kitagawa, Naoki Shiga, Narito Murakoshi

引用次数: 0

Beyond expert centers: National Survey on the Management of Autoimmune Pancreatitis in Everyday Clinical Practice in Germany. 超越专家中心：德国日常临床实践中自身免疫性胰腺炎管理的全国调查。

IF 2.2 4区医学

Pancreas Pub Date : 2026-09-21 DOI: 10.1097/MPA.0000000000002720

Michael Hirth, Laura Marx, Matthias P Ebert, Alexander Schneider

引用次数: 0